Search for Clinical Trial Results
Sezary Syndrome - 21 Studies Found
Status | Study |
Terminated |
Study Name: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Condition:
Date: 2012-06-19 Interventions:
|
Terminated |
Study Name: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Condition:
Date: 2005-08-08 Interventions: Drug: HuMax-CD4 (zanolimumab) Monoclonal Antibody, 12 weekly infusions. |
Completed |
Study Name: Immunization Against Tumor Cells in Sezary Syndrome Condition:
Date: 2004-12-17 Interventions: Biological: Autologous Dendritic Cell Vaccine |
Active, not recruiting |
Study Name: Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Condition:
Date: 2002-10-03 Interventions: Drug: Campath-1H |
Active, not recruiting |
Study Name: Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Condition:
Date: 2005-09-07 Interventions: Drug: alemtuzumab |
Recruiting |
Study Name: TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome Condition:
Date: 2016-06-30 Interventions:
|
Recruiting |
Study Name: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Condition:
|
Completed |
Study Name: VircapSeq Virus Detection in Sézary Syndrome Condition:
Date: 2016-07-15 |
Active, not recruiting |
Study Name: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome Condition:
|
Terminated |
Study Name: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Condition: Lymphoma Date: 1999-12-10 Interventions: Drug: temozolomide Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a to |